Dynamically growing company that renders services to the Russian and international pharmaceutical companies in the territory of Russia, the EAEU and CIS. LDV-group has been successfully operating in the pharmaceutical market for more than 10 years. The Company specializes in registration of medical devices, medicinal products, Active Pharmaceutical Ingredients, Food Supplements, as well as pre-audits in preparing for official Good Manufacturing Practice (GMP) audits.
The Company carries out its activities based on the current requirements of the regulatory authorities and the pharmaceutical market. LLC "LDV-group" maintains continuous cooperation with the leading research organizations, manufacturing enterprises and medical institutions of the Russian Federation, the CIS countries and Europe to gather up-to-date information on the development of innovative medicinal products that open up new directions in the area of medicine, as well as a detailed review of the safety, effectiveness and new properties of medicinal products already released.

Sun Pharma is an international pharmaceutical company headquartered in India, ranking among the top global pharma corporations. Since its foundation in 1983, Sun Pharma has been providing high-quality medicines, trusted by healthcare professionals and patients, to more than 100 countries worldwide. Sun Pharma has been operating in Russia since 1993 and is ranked among the top 30 leading pharmaceutical companies. The Russian division’s operations encompass production, distribution, and marketing of medicines in key therapeutic areas such as women’s and men’s health, common cold treatments, dermatology, central nervous system disorders, and ophthalmology. In 2024, Sun Pharma introduced its first innovative medication for basal cell carcinoma skin cancer, "Odomzo" (sonidegib), onto the Russian market. The company continues developing innovative drugs focusing on strategic areas like dermatology, oncological dermatology, rheumatology, and ophthalmology.

GEROPHARM is a biotechnology company and a leader in the Russian insulin market, producing over 35 drugs, including genetically engineered human insulins, original products, and generics. Today, GEROPHARM holds the first position in the Russian insulin market¹. All stages of insulin production are carried out at its own manufacturing facilities within the country.
Since 2024, the company has been developing orphan drugs and leads the market for obesity treatment products. The portfolio includes analogs of foreign drugs Ozempic®, Wegovy®, Mounjaro®. GEROPHARM is the leader in the Russian market for weight management drugs². The company operates a research center in Saint Petersburg and production complexes in the Moscow region and Saint Petersburg. Currently, the research center is developing more than 15 drugs in various therapeutic areas, including an innovative insulin with a weekly action profile. The launch of this innovative insulin is planned for 2028−2029. The company’s products are marketed not only in Russia but also in 14 countries of the CIS and beyond, including Mongolia, Venezuela, Morocco, and others. Representations and local manufacturing are established in Minsk, Almaty, Caracas, as well as production transfer projects in Azerbaijan, Belarus, and Venezuela.

R-Pharm Group introduces comprehensive solutions for the healthcare system and focuses on research, development, manufacturing and commercialization of pharmaceuticals, laboratory equipment and medical devices.
R-Pharm's 11 state-of-the-art manufacturing sites are functioning in accordance with international quality standards. More than 5,000 employees work in the offices and production facilities of the group of companies.
Today, R-Pharm's research pipeline contains more than 100 knowledge-intensive products, which make a serious contribution to the fight against high burden diseases.
The group has signed agreements on strategic partnership, production localization and technology transfer with the world’s leading manufacturers of pharmaceuticals and medical equipment.
Following corporate social responsibility policies, R-Pharm organizes projects aiming to increase awareness about dangerous diseases and foster a new generation of professionals in the pharmaceutical industry.

PJSC "PROMOMED" is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. The company’s structure includes its own unique world-class R&D center and a high-tech manufacturing facility — the "BIOKHIMIK" plant. Thanks to this, PROMOMED implements the full-cycle production concept "from idea to molecule, from molecule to patient". The company is developing a diversified portfolio of over 355 medicines in the top 10 segments of the pharmaceutical market, including those that have no analogues in Russia. Based on its own developments, PROMOMED produces drugs for the treatment of socially significant diseases: oncological, neurological, rheumatic, infectious diseases, diabetes mellitus, obesity, and others.
The company is an active participant in the system ensuring national drug security and import independence. In 2025, PROMOMED celebrates its 20th anniversary.

OOO "SmartBioTech" is the research and production complex established in accordance with international GMP standards and is one of the leading centers for the development, research and production of biopharmaceuticals, including but not limited to those against yellow fever, polio, and other socially significant diseases. The products developed by OOO "SmartBioTech" are prequalified by the World Health Organization (WHO) and are supplied to more than 70 countries worldwide.

Sotex Pharmaceutical Company is the core of the Protek Group’s manufacturing segment, one of the most high-tech and innovative pharmaceutical companies in Russia.
The Sotex plant, located in the Sergiev Posad district of the Moscow region, was commissioned in 2005 and was designed from the outset to comply with Good Manufacturing Practice (GMP) requirements. The facility covers the full production cycle: preparing injection solutions, filling ampoules and syringes, followed by packaging, labeling, and shipping to the warehouse. The plant also operates a production line for genetically engineered drugs in prefilled syringes with automatic needle protection devices. Sotex holds GMP certificates from authorized regulatory bodies in the Russian Federation and the EU. Sotex’s portfolio includes over 150 medicinal products. Main therapeutic areas: neurology, oncology, rheumatology, nephrology, anti-cold drugs, and others.

LLC "National Center of Standard Samples" (NCSS LLC) is a specialized organization established by the FSI "SID & GP" of the Ministry of Industry and. Trade of the Russian Federation. The Center majors in the development, production, and certification of reference standards for the pharmaceutical and related industries. It holds an international certificate of conformity under GOST R ISO 9001−2015, as
well as a license and the GMP certificate. The Center carries out quality control of medicines, develops analytical methods, implements import substitution projects, and expands the use of reference standards across various fields.

A multi-faceted learning, research and expert platform, the Eurasian Academy of Good Practices fosters the growth of the pharmaceutical industry. The Academy was established upon the initiative of the EAEU pharmaceutical inspectorates with the support of the Ministry of Industry and Trade of the Russian Federation. The Academy's Board of Trustees includes representatives of the EAEU regulatory authorities, Russian and international pharmaceutical associations, and leading pharma companies.
Our key goals:

• Ensuring strategic integration of pharmaceutical education in lifelong learning: college → university → continuing professional education
• Assisting regulatory authorities and drug circulation entities in GxP appraisal & consulting
• Helping Russia's pharmaceutical industry attain technological independence by fostering innovation
• Promoting the domestic pharmaceutical industry and its achievements

What we do:
TRAINING | RESEARCH & CONSULTING | APPRAISAL | OUTREACH ACTIVITIES

GxP News is an industry media outlet focused on the professional pharmaceutical community. It’s an international information platform for dialogue between the pharmaceutical industry and regulators, a venue for the exchange of experience and opinions. Our information resources include a website and a print magazine. We publish daily news, expert articles, columns, and interviews. We are a media partner
for all major industry events.

Pharmstandard Group is one of the leaders in the Russian pharmaceutical market. The Group’s areas of priority are the development and manufacturing of advanced, high-quality and affordable medicinal products in demand by the healthcare system. The portfolio of Pharmstandard Group includes medicinal products used in ophthalmology, endocrinology, and for the treatment of respiratory organs, the musculoskeletal system, oncological, hematological, cardiovascular, orphan, infectious and a number of other diseases. The sales territory covers Russia and foreign countries.
Manufacturing sites: Phs-Leksredstva JSC (Kursk), Pharmstandard-UfaVITA JSC (Ufa), PHS-Tomskhimpharm JSC (Tomsk), LEKKO CJSC (Vladimir region). Pharmstandard is engaged in the development of a modern complex for manufacturing solid dosage forms by OTCpharm Pro JSC near the city of Kaliningrad and owns a share in the authorized capital of Daliompharma LLC, specializing in processing donor human blood plasma in the Republic of Belarus. The total manufacturing capacity of Pharmstandard Group exceeds 1.7 bln medicine packs per year. The activities of Pharmstandard Group are performed in strict compliance with the Russian and international rules for the manufacturing and quality control of medicines.

Pharmasyntez is one of the leading biopharmaceutical companies in Russia and operates across various segments of the healthcare industry. This includes research, development, production, and distribution of medicines for the treatment of socially significant diseases, innovative medicines, and active pharmaceutical ingredients. The production facilities of the Pharmasyntez Group are represented by five high-tech plants across Russia: in Ussuriysk, Irkutsk, Bratsk, Tyumen, and St. Petersburg. The annual production output of the Pharmasyntez Group exceeds 100 million packages. The company employs over 5,000 people. Pharmasyntez develops and manufactures modern medicines for a wide range of medical applications, including oncology, hematology, endocrinology, immunology, and cardiology, as well as medicines for the treatment of orphan, hormonal, infectious, autoimmune, and cardiovascular diseases. The company’s portfolio includes medicines for the treatment of diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, chronic renal failure, as well as products for maintaining patients with severe conditions, for example, solutions for parenteral nutrition. The R&D center for biotechnological medicines of Pharmasyntez Group is one of the largest in Russia. Its ongoing research and development projects are aimed at creating a new generation of innovative treatment methods in oncohematology, gynecology, virology, and endocrinology. The company’s product portfolio includes more than 300 medicines and over 80 pharmaceutical ingredients. More than 80% of the company’s products are included in the list of life-saving medicines. Pharmasyntez is one of the largest investors in the Russian pharmaceutical industry. To date, over 23 billion rubles (280 million USD) have been invested in the extension of production capacities and new research and development activities. Consolidated revenue for 2024 amounted to 50.1 billion rubles (640 million USD).

The modern, dynamically developing Russian pharmaceutical company is one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates. Skopinpharm is a developer and manufacturer of medicines and one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses. The company’s turnover amounted to more than 44.1 billion rubles by 2024. The company operates in the following key areas: manufacture of plasma-derived medicinal products, cytostatics, and medicinal products used for the treatment of various oncological diseases. As part of developing these business areas, the company has constructed new manufacturing and storage buildings, performs technology transfer of unique pharmaceutical manufacturing processes, and has built a plasma storage facility with a laboratory unit, which will ensure proper storage of plasma intended for fractionation (raw materials for the manufacture of human plasma-derived medicinal products). At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created, and a voluntary donation program is being developed. Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU.